---
title: "MBX Biosciences, Inc. (MBX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MBX.US.md"
symbol: "MBX.US"
name: "MBX Biosciences, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T10:34:52.141Z"
locales:
  - [en](https://longbridge.com/en/quote/MBX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MBX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MBX.US.md)
---

# MBX Biosciences, Inc. (MBX.US)

## Company Overview

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [mbxbio.com](https://mbxbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -16.67 | 202 | - | - | - |
| PB | 3.30 | 124 | 4.03 | 3.35 | 1.79 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 75% |
| Overweight | 2 | 17% |
| Sell | 1 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 30.39 |
| Highest Target | 91.00 |
| Lowest Target | 20.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MBX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MBX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MBX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MBX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**